To access the professional site for information about BETASERON® (interferon beta-1b) please confirm that you are a healthcare professional.
You will only be prompted once per visit to the website.
Models used for illustrative purposes only.
BETASERON® (interferon beta-1b) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
In patients with clinically isolated syndrome (CIS), BETASERON® was PROVEN to
In patients with relapsing-remitting multiple sclerosis (RRMS), BETASERON was PROVEN to
In a 2-year study, 292 patients with clinically isolated syndrome* who started treatment early with BETASERON significantly reduced their likelihood of having a second flare-up compared with 176 patients on placebo
BETASERON cut risk of a second flare-up in half
*Patients included in the BENEFIT Study experienced a first neurological event suggestive of multiple sclerosis, which is also referred to as clinically isolated
syndrome. Patients also had at least 2 lesions on a T2-weighted brain MRI scan that did not cause any symptoms.
†By proportional hazard ratio regression adjusted for age/gender/steroids/T2 lesions/Gd lesions.
MRI data from a 2-year study showed that BETASERON patients with the first symptoms of MS had fewer newly active lesions at 2 years
BETASERON reduced the number of brain lesions
fewer newly active lesions‡
In a 2-year study, 124 patients taking BETASERON had 31% fewer relapses than 123 patients taking placebo
The second main result showed the proportion of patients who had not had a flare-up at 2 years did not significantly differ between the placebo (16%) and BETASERON (25%) treatment groups
BETASERON cut the frequency of
It's important to know the possible risks and benefits of BETASERON. Make sure you talk to your doctor to understand which possible side effects are more serious than others, as well as those that are more common.Learn more about safety